A Prospective, Observational Study of the Real World Safety and Effectiveness of the Ultimaster Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions in All-comer Patients (MASTER Trial)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary)
Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Ischaemia; Unstable angina pectoris
Focus Therapeutic Use
Acronyms MASTER

Most Recent Events

13 Mar 2024 Planned End Date changed from 24 Aug 2024 to 13 Feb 2025.
13 Mar 2024 Planned primary completion date changed from 24 Aug 2024 to 13 Feb 2025.
10 Jan 2024 Planned End Date changed from 30 Jun 2024 to 24 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight